Lundbeck Places Significant Bet On Myriad Alzheimer’s Candidate Flurizan

EU marketing partnership brings Myriad considerable royalties and milestones if compound wins approval as first drug to delay Alzheimer’s progression.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet